| Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? D Has Simsek, S Kuyumcu, S Karadogan, M Oflas, EG Isik, ZG Ozkan, ... Annals of Nuclear Medicine 35, 680-690, 2021 | 15 | 2021 |
| Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan, E Akar, B Çakar, ... European urology focus 7 (5), 1061-1066, 2021 | 14 | 2021 |
| Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab D Tural, ÖF Ölmez, AT Sümbül, N Özhan, B Çakar, O Köstek, M Ekenel, ... International journal of clinical oncology 26, 1506-1513, 2021 | 12 | 2021 |
| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 136, 2023 | 11 | 2023 |
| FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer S Ay, MM Atcı, R Arıkan, Ö Dülgar, DT Özyükseler, N Paksoy, İ Doğan, ... Journal of Chemotherapy 34 (7), 465-471, 2022 | 9 | 2022 |
| A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions S Demir, A Gelincik, R Coskun, G Ozkan, N Demir, N Paksoy, S Beyaz, ... Annals of Allergy, Asthma & Immunology 123 (4), 394-397, 2019 | 8 | 2019 |
| Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group M Gürbüz, Y Kutlu, E Akkuş, EB Köksoy, N Köse, BB Öven, BO Uluç, ... Journal of cancer research and clinical oncology 148 (12), 3547-3555, 2022 | 7 | 2022 |
| Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression I Dogan, E Aydin, N Khanmammadov, N Paksoy, P Saip, A Aydiner Scientific Reports 13 (1), 8779, 2023 | 6 | 2023 |
| Analysis of the factors associated with diagnostic skin test positivity in immediate‐type hypersensitivity reactions due to proton pump inhibitors. S Kepil Özdemir, A Gelincik, N Paksoy, G Köycü Buhari, F Öner Erkekol, ... Allergy 74 (6), 2019 | 5 | 2019 |
| The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification?(Turkish Oncology … M Hizal, B Bilgin, N Paksoy, MM Atcı, S Kahraman, S Kılıçkap, DC Güven, ... Journal of Cancer Research and Clinical Oncology 149 (8), 4141-4148, 2023 | 4 | 2023 |
| Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study N Paksoy, N Khanmammadov, İ Doğan, F Ferhatoğlu, MA Ahmed, ... Medicine 102 (5), e32866, 2023 | 4 | 2023 |
| Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report N Paksoy, S Erdem, M Karaca, N Ak, M Pehlivan, IK Yirgin, Y Ozluk, ... Journal of Oncology Pharmacy Practice 28 (1), 215-221, 2022 | 4 | 2022 |
| Clinicopathological and Prognostic features of 67 cases with pulmonary Sarcomatoid carcinoma: an 18-year single-centre experience F Ferhatoglu, F Amirov, B Ozkan, M Kara, A Toker, N Ak, E Aydın, ... Oncology Research and Treatment 44 (11), 590-601, 2021 | 4 | 2021 |
| Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer S Kahraman, E Erul, M Seyyar, O Gumusay, E Bayram, BC Demirel, ... Future Oncology 19 (10), 727-736, 2023 | 3 | 2023 |
| Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study N Paksoy, N Khanmammadov, İ Doğan, F Ferhatoğlu, A Yildiz, N Ak, ... Medicine 101 (45), e31726, 2022 | 3 | 2022 |
| Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group Ç Ünal, A Azizy, S Karabulut, D Taştekin, A Akyıldız, S Yaşar, Ş Yalçın, ... The oncologist 28 (10), 875-884, 2023 | 2 | 2023 |
| The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study M Hizal, B Bilgin, N Paksoy, Ö Açıkgöz, A Sezer, M Gürbüz, N Ak, Ş Yücel, ... Journal of Cancer Research and Clinical Oncology, 1-8, 2022 | 2 | 2022 |
| Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study I Cil, A Kucukarda, MM Atcı, S Secmeler, N Paksoy, F Ferhatoglu, N Ak, ... Tumori Journal 108 (1), 19-25, 2022 | 2 | 2022 |
| Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer EŞ Taşçı, B Oyan, Ö Sönmez, AU Mutlu, MM Atcı, A Sakin, İ Öner, ... BMC cancer 24 (1), 16, 2024 | 1 | 2024 |
| Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience D Tastekin, N Paksoy, I Dogan, F Ferhatoglu, N Khanmammadov, ... Journal of cancer research and therapeutics 19 (2), 253-258, 2023 | 1 | 2023 |
